The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
Morrow
S A
SA
Department of Clinical Neurosciences, University of Western Ontario, London, Ontario, Canada.
Stoian
C A
CA
Dmitrovic
J
J
Chan
S C
SC
Metz
L M
LM
D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D001682:Biological Availability; D001711:Biotransformation; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008099:Liver / Q000378:metabolism; D008297:Male; D008775:Methylprednisolone / Q000097:blood; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000378:metabolism; D011239:Prednisolone / Q000097:blood; D011241:Prednisone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D008776:Methylprednisolone Hemisuccinate; D011239:Prednisolone; D011241:Prednisone; D008775:Methylprednisolone